表紙
市場調查報告書

癌症疫苗的全球市場 - 各技術、各類型、各症狀、各終端用戶:機會分析與產業預測 (2020∼2027年)

Cancer Vaccines Market by Technology, Type, Indication, and End User : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版商 Allied Market Research 商品編碼 955623
出版日期 內容資訊 英文 284 Pages
商品交期: 2-3個工作天內
價格
癌症疫苗的全球市場 - 各技術、各類型、各症狀、各終端用戶:機會分析與產業預測 (2020∼2027年) Cancer Vaccines Market by Technology, Type, Indication, and End User : Global Opportunity Analysis and Industry Forecast, 2020-2027
出版日期: 2020年07月01日內容資訊: 英文 284 Pages
簡介

全球癌症疫苗的市場規模,2019年達41億8800萬美元,預計2027年達73億300萬美元。還有2020∼2027年的年複合成長率預計成為12.6%。市場成長的主要原因,是乳癌、前列腺癌症、子宮頸癌症、肺癌症等的盛行率上升,及公民營雙方投入巨額研究資金等。還有對癌症疫苗的優點的知識普及,及人類乳突病毒 (HPV) 感染疾病的盛行率增加,新疫苗的上市等,也對促進市場有所貢獻。另一方面,開發費用的主要開發期間長也有可能妨礙市場成長。

本報告提供全球癌症疫苗的市場相關分析,產品概要和市場基本結構、最新趨勢,主要的推動及阻礙市場要素,今後的市場機會,市場規模的成果值、預測值 (今後8年份),各技術、各類型、各症狀、各終端用戶、各地區的詳細趨勢,主要企業的簡介等相關調查。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
    • 主要的投資財源
    • 主要的成功策略
  • 波特的五力分析
  • 法律規範:國際/國內法規
  • 市場佔有率分析 (2019年)
  • 市場動態
    • 推動市場要素
      • 人類乳突病毒(HPV)癌症盛行率上升
      • 預防性癌症疫苗的給藥增加
      • 新的癌症疫苗的開發增加
      • 市場上新的癌症疫苗的銷售與核准
    • 阻礙市場要素
      • 癌症疫苗的開發必要的高成本與時間長
    • 市場機會
      • 新興市場高成長預測
    • 影響度分析

第4章 癌症疫苗的市場:各技術

  • 概況
    • 市場規模與其預測
  • 樹突狀細胞(DC)癌症疫苗
    • 主要的市場趨勢,成長要素,機會
    • 市場規模與其預測:各地區
    • 市場分析:各國
  • 基因重組癌症疫苗
  • 抗原/輔助治療癌症疫苗
  • 病毒載體、DNA癌症疫苗

第5章 癌症疫苗的市場:各類型

  • 概況
  • 市場規模與其預測
  • 預防用癌症疫苗
  • 治療用癌症疫苗

第6章 癌症疫苗市場:各症狀

  • 概況
  • 市場規模與其預測
  • 子宮頸癌症
  • 前列腺癌症
  • 其他症狀

第7章 癌症疫苗市場:各終端用戶

  • 概況
  • 市場規模與其預測
  • 兒童
  • 成人

第8章 癌症疫苗市場:各地區

  • 概要
    • 市場規模與其預測
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他的歐洲各國
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他的亞太地區各國
  • 南美、中東、非洲 (LAMEA)
    • 巴西
    • 阿根廷
    • 土耳其
    • 南非
    • 其他的LAMEA各國

第9章 企業簡介

  • Advaxis Inc.
  • Amgen Inc.
  • Dynavax Technologies Corporation
  • Generex Biotechnology Corporation
  • GlaxoSmithKline plc (GSK)
  • Immunocellular Therapeutics, Ltd
  • Merck & Co., Inc.
  • SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION)
  • UbiVac
  • Vaccinogen, Inc.
目錄
Product Code: A01134

Title:
Cancer Vaccines Market by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, and Viral Vector & DNA Cancer Vaccines), Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Indication (Cervical Cancer, Prostate Cancer, and Others), and End User (Pediatrics and Adults): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global cancer vaccines market was valued at $4,188 million in 2019, and is projected to reach $7,303 million by 2027, registering a CAGR of 12.6% from 2020 to 2027.

Vaccine is a biological preparation that strengthens the immune system and provides acquired immunity against a specific pathogen. Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer. In addition, it offers numerous benefits as it can stop the growth of tumor cells, prevents cancer relapse, and destroys tumor cells that are left behind after treatment. There are two types of vaccines available in market, namely, preventive cancer vaccines and therapeutic cancer vaccines. Preventive cancer vaccines are traditional cancer vaccines used in healthy people to prevent cancer. Therapeutic cancer vaccines are type of immunotherapy vaccines used for metastatic prostate cancer, human papillomavirus (HPV), and hepatitis B virus.

The factors that drive the cancer vaccines market are rise in prevalence of cancer such as breast cancer, prostate cancer, and cervical, lung cancer globally, and surge in investments and governmental funding for the development of cancer vaccines by manufacturers. In addition, increase in cancer vaccines usage combined with other therapies, surge in demand for cancer vaccines, rise in public awareness toward benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines further fuel the market growth. However, high cost for developing cancer vaccines and longer time span required for manufacturing a single vaccine are anticipated to restrict the market growth. Furthermore, growth in transition from prophylactic to therapeutic cancer vaccines is expected to offer lucrative opportunities in the near future.

The global cancer vaccines market is segmented on the basis of technology, type, indication, end user, and region. By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines. By type, it is bifurcated into preventive cancer vaccines and therapeutic cancer vaccines. By indication, it is classified into cervical cancer, prostate cancer, and others. By end user, it is divided into pediatric and adult. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.

A comprehensive analysis of four regions is provided to determine the existing opportunities.

The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Technology

  • Dendritic Cells (DC) Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Antigen/Adjuvant Cancer Vaccines
  • Viral Vector & DNA Cancer Vaccines

By Indication

  • Cervical Cancer
  • Prostate Cancer
  • Others

By Type

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines

By End User

  • Pediatrics
  • Adults

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Argentina
  • Turkey
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Advaxis Inc.
  • Amgen Inc.
  • Dynavax Technologies Corporation
  • Generex Biotechnology Corporation
  • GlaxoSmithKline plc (GSK)
  • Immunocellular Therapeutics, Ltd
  • Merck & Co., Inc.
  • Sanpower Group Co. Ltd. (Dendereon Corporation)
  • UbiVac
  • Vaccinogen, Inc.
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Oxford BioMedica.
  • Juvaris Biotherapeutics
  • Prima BioMed

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Benefits for Stakeholders
  • 1.3. Key Market Segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
  • 2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top investment pockets.
    • 3.2.2. Top winning strategies
  • 3.3. Porter's five force analysis
  • 3.4. Regulatory Framework
    • 3.4.1. FDA
    • 3.4.2. CE Mark
    • 3.4.3. Therapeutic Goods Administration (TGA)
    • 3.4.4. Ministry of Health, Labour and Welfare (MHLW)
  • 3.5. Market Share Analysis, 2019
  • 3.6. Market Dynamics
    • 3.6.1. Drivers
      • 3.6.1.1. Rise in prevalence of human papilloma virus (HPV) cancer
      • 3.6.1.2. Increase in administration of prophylactic cancer vaccines
      • 3.6.1.3. Rise in development of new cancer vaccines
      • 3.6.1.4. Launch and approval of new cancer vaccines in the market
    • 3.6.2. Restraints
      • 3.6.2.1. High cost and longer timelines required for development of cancer vaccines
    • 3.6.3. Opportunities
      • 3.6.3.1. High growth prospects in emerging markets
    • 3.6.4. Impact analysis

CHAPTER 4: CANCER VACCINES MARKET, BY TECHNOLOGY

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Dendritic Cells (DC) Cancer Vaccines
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market analysis by country
  • 4.3. Recombinant Cancer Vaccines
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market analysis by country
  • 4.4. Antigen/Adjuvent Cancer Vaccines
    • 4.4.1. Key market trends, growth factors, and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market analysis by country
  • 4.5. Viral Vector and DNA Cancer Vaccines
    • 4.5.1. Key market trends, growth factors, and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market analysis by country

CHAPTER 5: CANCER VACCINES MARKET, BY TYPES

  • 5.1. Overview
  • 5.2. Market size and forecast
  • 5.3. Preventive Cancer Vaccines
    • 5.3.1. Market size and forecast, by region
    • 5.3.2. Market analysis, by country
  • 5.4. Therapeutic Cancer Vaccines
    • 5.4.1. Market size and forecast, by region
    • 5.4.2. Market analysis, by country

CHAPTER 6: CANCER VACCINES MARKET, BY INDICATION

  • 6.1. Overview
  • 6.2. Market size and forecast
  • 6.3. Cervical Cancer
    • 6.3.1. Market size and forecast, by region
    • 6.3.2. Market analysis, by country
  • 6.4. Prostate Cancer
    • 6.4.1. Market size and forecast, by region
    • 6.4.2. Market analysis, by country
  • 6.5. Other Indications
    • 6.5.1. Market size and forecast, by region
    • 6.5.2. Market analysis, by country

CHAPTER 7: CANCER VACCINES MARKET, BY END USER

  • 7.1. Overview
  • 7.2. Market size and forecast
  • 7.3. Pediatrics
    • 7.3.1. Market size and forecast, by region
    • 7.3.2. Market analysis, by country
  • 7.4. Adults
    • 7.4.1. Market size and forecast, by region
    • 7.4.2. Market analysis, by country

CHAPTER 8: CANCER VACCINES MARKET, BY REGION

  • 8.1. OVERVIEW
    • 8.1.1. Market size and forecast
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors, and opportunities
    • 8.2.2. North America cancer vaccines market, by country
      • 8.2.2.1. U.S.
      • 8.2.2.1.1. U.S. cancer vaccines market, by technology
      • 8.2.2.1.2. U.S. cancer vaccines market, by type
      • 8.2.2.1.3. U.S. cancer vaccines market, by Indication
      • 8.2.2.1.4. U.S. cancer vaccines market, by end user
      • 8.2.2.3. Canada
      • 8.2.2.3.1. Canada cancer vaccines market, by technology
      • 8.2.2.3.2. Canada cancer vaccines market, by type
      • 8.2.2.3.3. Canada cancer vaccines market, by indication
      • 8.2.2.3.4. Canada cancer vaccines market, by end user
      • 8.2.2.5. Mexico
      • 8.2.2.5.1. Mexico cancer vaccines market, by technology
      • 8.2.2.5.2. Mexico cancer vaccines market, by type
      • 8.2.2.5.3. Mexico cancer vaccines market, by indication
      • 8.2.2.5.4. Mexico cancer vaccines market, by end user
    • 8.2.3. North America cancer vaccines market, by technology
    • 8.2.4. North America cancer vaccines market, by type
    • 8.2.5. North America cancer vaccines market, by indication
    • 8.2.6. North America cancer vaccines market, by end user
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors, and opportunities
    • 8.3.2. Europe cancer vaccines market, by country
      • 8.3.2.1. Germany
      • 8.3.2.1.1. Germany cancer vaccines market, by technology
      • 8.3.2.1.2. Germany cancer vaccines market, by type
      • 8.3.2.1.3. Germany cancer vaccines market, by indication
      • 8.3.2.1.4. Germany cancer vaccines market, by end user
      • 8.3.2.2. France
      • 8.3.2.2.1. France cancer vaccines market, by technology
      • 8.3.2.2.2. France cancer vaccines market, by type
      • 8.3.2.2.3. France cancer vaccines market, by indication
      • 8.3.2.2.4. France cancer vaccines market, by end user
      • 8.3.2.3. UK
      • 8.3.2.3.1. UK cancer vaccines market, by technology
      • 8.3.2.3.2. UK cancer vaccines market, by type
      • 8.3.2.3.3. UK cancer vaccines market, by indication
      • 8.3.2.3.4. UK cancer vaccines market, by end user
      • 8.3.2.4. Italy
      • 8.3.2.4.1. Italy cancer vaccines market, by technology
      • 8.3.2.4.2. Italy cancer vaccines market, by type
      • 8.3.2.4.3. Italy cancer vaccines market, by indication
      • 8.3.2.4.4. Italy cancer vaccines market, by end user
      • 8.3.2.5. Spain

The Spain cancer vaccines market was valued at $107.67 million in 2019, and is projected to reach $158.00 million by 2027, registering a CAGR of 9.5%.

      • 8.3.2.5.1. Spain cancer vaccines market, by technology
      • 8.3.2.5.2. Spain cancer vaccines market, by type
      • 8.3.2.5.3. Spain cancer vaccines market, by indication
      • 8.3.2.5.4. Spain cancer vaccines market, by end user
      • 8.3.2.6. Rest of Europe
      • 8.3.2.6.1. Rest of Europe cancer vaccines market, by technology
      • 8.3.2.6.2. Rest of Europe cancer vaccines market, by type
      • 8.3.2.6.3. Rest of Europe cancer vaccines market, by indication
      • 8.3.2.6.4. Rest of Europe cancer vaccines market, by end user
    • 8.3.3. Europe cancer vaccines market, by technology
    • 8.3.4. Europe cancer vaccines market, by type
    • 8.3.5. Europe cancer vaccines market, by indication
    • 8.3.6. Europe cancer vaccines market, by end user
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends and opportunities
    • 8.4.2. Asia-Pacific cancer vaccines market, by country
      • 8.4.2.1. Japan
      • 8.4.2.1.1. Japan cancer vaccines market, by technology
      • 8.4.2.1.2. Japan cancer vaccines market, by type
      • 8.4.2.1.3. Japan cancer vaccines market, by indication
      • 8.4.2.1.4. Japan cancer vaccines market, by end user
      • 8.4.2.2. China
      • 8.4.2.2.1. China cancer vaccines market, by technology
      • 8.4.2.2.2. China cancer vaccines market, by type
      • 8.4.2.2.3. China cancer vaccines market, by indication
      • 8.4.2.2.4. China cancer vaccines market, by end user
      • 8.4.2.3. Australia
      • 8.4.2.3.1. Australia cancer vaccines market, by technology
      • 8.4.2.3.2. Australia cancer vaccines market, by type
      • 8.4.2.3.3. Australia cancer vaccines market, by indication
      • 8.4.2.3.4. Australia cancer vaccines market, by end user
      • 8.4.2.4. India
      • 8.4.2.4.1. India cancer vaccines market, by technology
      • 8.4.2.4.2. India cancer vaccines market, by type
      • 8.4.2.4.3. India cancer vaccines market, by indication
      • 8.4.2.4.4. India cancer vaccines market, by end user
      • 8.4.2.5. South Korea
      • 8.4.2.5.1. South Korea cancer vaccines market, by technology
      • 8.4.2.5.2. South Korea cancer vaccines market, by type
      • 8.4.2.5.3. South Korea cancer vaccines market, by indication
      • 8.4.2.5.4. South Korea cancer vaccines market, by end user
      • 8.4.2.6. Rest of Asia-Pacific
      • 8.4.2.6.1. Rest of Asia-Pacific cancer vaccines market, by technology
      • 8.4.2.6.2. Rest of Asia-Pacific cancer vaccines market, by type
      • 8.4.2.6.3. Rest of Asia-Pacific cancer vaccines market, by indication
      • 8.4.2.6.4. Rest of Asia-Pacific cancer vaccines market, by end user
    • 8.4.3. Asia-Pacific cancer vaccines market, by technology
    • 8.4.4. Asia-Pacific cancer vaccines market, by type
    • 8.4.5. Asia-Pacific cancer vaccines market, by indication
    • 8.4.6. Asia-Pacific cancer vaccines market, by end user
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors, and opportunities
    • 8.5.2. LAMEA cancer vaccines market, by country
      • 8.5.2.1. Brazil
      • 8.5.2.1.1. Brazil cancer vaccines market, by technology
      • 8.5.2.1.2. Brazil cancer vaccines market, by type
      • 8.5.2.1.3. Brazil cancer vaccines market, by indication
      • 8.5.2.1.4. Brazil cancer vaccines market, by end user
      • 8.5.2.2. Argentina
      • 8.5.2.2.1. Argentina cancer vaccines market, by technology
      • 8.5.2.2.2. Argentina cancer vaccines market, by type
      • 8.5.2.2.3. Argentina cancer vaccines market, by indication
      • 8.5.2.2.4. Argentina cancer vaccines market, by end user
      • 8.5.2.3. Turkey
      • 8.5.2.3.1. Turkey cancer vaccines market, by technology
      • 8.5.2.3.2. Turkey cancer vaccines market, by type
      • 8.5.2.3.3. Turkey cancer vaccines market, by indication
      • 8.5.2.3.4. Turkey cancer vaccines market, by end user
      • 8.5.2.4. South Africa
      • 8.5.2.4.1. South Africa cancer vaccines market, by technology
      • 8.5.2.4.2. South Africa cancer vaccines market, by type
      • 8.5.2.4.3. South Africa cancer vaccines market, by indication
      • 8.5.2.4.4. South Africa cancer vaccines market, by end user
      • 8.5.2.5. Rest of LAMEA
      • 8.5.2.5.1. Rest of LAMEA cancer vaccines market, by technology
      • 8.5.2.5.2. Rest of LAMEA cancer vaccines market, by type
      • 8.5.2.5.3. Rest of LAMEA cancer vaccines market, by indication
      • 8.5.2.5.4. Rest of LAMEA cancer vaccines market, by end user
    • 8.5.3. LAMEA cancer vaccines market, by technology
    • 8.5.4. LAMEA cancer vaccines market, by type
    • 8.5.5. LAMEA cancer vaccines market, by indication
    • 8.5.6. LAMEA cancer vaccines market, by end user

CHAPTER 9: COMPANY PROFILES

  • 9.1. Advaxis Inc.
    • 9.1.1. Company overview
    • 9.1.2. Company snapshot
    • 9.1.3. Operating business segments
    • 9.1.4. Product portfolio
    • 9.1.5. Business performance
    • 9.1.6. Key strategic moves and developments
  • 9.2. Amgen Inc.
    • 9.2.1. Company overview
    • 9.2.2. Company snapshot
    • 9.2.3. Operating business segments
    • 9.2.4. Product portfolio
    • 9.2.5. Business performance
  • 9.3. Dynavax Technologies Corporation
    • 9.3.1. Company overview
    • 9.3.2. Company snapshot
    • 9.3.3. Operating business segments
    • 9.3.4. Product portfolio
    • 9.3.5. Business performance
  • 9.4. Generex Biotechnology Corporation
    • 9.4.1. Company overview
    • 9.4.2. Company snapshot
    • 9.4.3. Operating business segments
    • 9.4.4. Product portfolio
    • 9.4.5. Business performance
  • 9.5. GlaxoSmithKline plc (GSK)
    • 9.5.1. Company overview
    • 9.5.2. Company snapshot
    • 9.5.3. Operating business segments
    • 9.5.4. Product portfolio
    • 9.5.5. Business performance
    • 9.5.6. Key strategic moves and developments
  • 9.6. Immunocellular Therapeutics, Ltd
    • 9.6.1. Company overview
    • 9.6.2. Company snapshot
    • 9.6.3. Operating business segments
    • 9.6.4. Product portfolio
  • 9.7. Merck & Co., Inc.
    • 9.7.1. Company overview
    • 9.7.2. Company snapshot
    • 9.7.3. Operating business segments
    • 9.7.4. Product portfolio
    • 9.7.5. Business performance
    • 9.7.6. Key strategic moves and developments
  • 9.8. SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION)
    • 9.8.1. Company overview
    • 9.8.2. Company snapshot
    • 9.8.3. Operating business segments
    • 9.8.4. Product portfolio
    • 9.8.5. Key strategic moves and developments
  • 9.9. UbiVac
    • 9.9.1. Company overview
    • 9.9.2. Company snapshot
    • 9.9.3. Operating business segments
    • 9.9.4. Product portfolio
    • 9.9.5. Key strategic moves and developments
  • 9.10. Vaccinogen, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Company snapshot
    • 9.10.3. Operating business segments
    • 9.10.4. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 02. DENDRITIC CELLS (DC) CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
  • TABLE 03. RECOMBINANT CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
  • TABLE 04. ANTIGEN/ADJUVENT CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
  • TABLE 05. VIRAL VECTOR AND DNA CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
  • TABLE 06. GLOBAL CANCER VACCINES MARKET, BY TYPES, 2019-2027 ($MILLION)
  • TABLE 07. PREVENTIVE CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
  • TABLE 08. THERAPEUTIC CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
  • TABLE 09. GLOBAL CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 10. CERVICAL CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
  • TABLE 11. PROSTATE CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
  • TABLE 12. OTHERS INDICATIONS CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
  • TABLE 13. GLOBAL CANCER VACCINES MARKET REVENUE, BY END USER, 2019-2027 ($MILLION)
  • TABLE 14. PEDIATRICS CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
  • TABLE 15. ADULTS CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
  • TABLE 16. CANCER VACCINES MARKET REVENUE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17. NORTH AMERICA CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 18. U.S. CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 19. U.S. CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 20. U.S. CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 21. U.S. CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 22. CANADA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 23. CANADA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 24. CANADA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 25. CANADA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 26. MEXICO CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 27. MEXICO CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 28. MEXICO CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 29. MEXICO CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 30. NORTH AMERICA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 31. NORTH AMERICA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 32. NORTH AMERICA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 33. NORTH AMERICA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 34. EUROPE CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 35. GERMANY CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 36. GERMANY CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 37. GERMANY CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 38. GERMANY CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 39. FRANCE CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 40. FRANCE CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 41. FRANCE CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 42. FRANCE CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 43. UK CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 44. UK CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 45. UK CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 46. UK CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 47. ITALY CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 48. ITALY CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 49. ITALY CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 50. ITALY CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 51. SPAIN CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 52. SPAIN CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 53. SPAIN CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 54. SPAIN CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 55. REST OF EUROPE CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 56. REST OF EUROPE CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 57. REST OF EUROPE CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 58. REST OF EUROPE CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 59. EUROPE CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 60. EUROPE CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 61. EUROPE CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 62. EUROPE CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 63. ASIA-PACIFIC CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 64. JAPAN CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 65. JAPAN CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 66. JAPAN CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 67. JAPAN CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 68. CHINA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 69. CHINA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 70. CHINA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 71. CHINA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 72. AUSTRALIA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 73. AUSTRALIA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 74. AUSTRALIA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 75. AUSTRALIA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 76. INDIA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 77. INDIA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 78. INDIA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 79. INDIA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 80. SOUTH KOREA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 81. SOUTH KOREA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 82. SOUTH KOREA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 83. SOUTH KOREA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 87. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 88. ASIA-PACIFIC CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 89. ASIA-PACIFIC CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 90. ASIA-PACIFIC CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 91. ASIA-PACIFIC CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 92. LAMEA CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 93. BRAZIL CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 94. BRAZIL CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 95. BRAZIL CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 96. BRAZIL CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 97. ARGENTINA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 98. ARGENTINA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 99. ARGENTINA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 100. ARGENTINA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 101. TURKEY CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 102. TURKEY CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 103. TURKEY CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 104. TURKEY CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 105. SOUTH AFRICA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 106. SOUTH AFRICA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 107. SOUTH AFRICA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 108. SOUTH AFRICA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 109. REST OF LAMEA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 110. REST OF LAMEA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 111. REST OF LAMEA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 112. REST OF LAMEA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 113. LAMEA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 114. LAMEA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 115. LAMEA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 116. LAMEA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 117. ADVAXIS: COMPANY SNAPSHOT
  • TABLE 118. ADVAXIS: PRODUCT PORTFOLIO
  • TABLE 119. ADVAXIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. AMGEN: COMPANY SNAPSHOT
  • TABLE 121. AMGEN: PRODUCT PORTFOLIO
  • TABLE 122. DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 123. DYNAVAX TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 124. GENEREX BIOTECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 125. GENEREX BIOTECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 126. GSK: COMPANY SNAPSHOT
  • TABLE 127. GLAXOSMITHKLINE PLC.: OERATING SEGMENT
  • TABLE 128. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 129. GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. IMMUNOCELLULAR: COMPANY SNAPSHOT
  • TABLE 131. IMMUNOCELLULAR: PRODUCT PORTFOLIO
  • TABLE 132. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 133. MERCK & CO., INC.: OPERATING SEGMENTS
  • TABLE 134. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 135. MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. SANPOWER GROUP: COMPANY SNAPSHOT
  • TABLE 137. SANPOWER GROUP: OERATING SEGMENT
  • TABLE 138. SANPOWER GROUP: PRODUCT PORTFOLIO
  • TABLE 139. SANPOWER GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. UBIVAC: COMPANY SNAPSHOT
  • TABLE 141. UBIVAC.: PRODUCT PORTFOLIO
  • TABLE 142. UBIVAC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. VACCINOGEN: COMPANY SNAPSHOT
  • TABLE 144. VACCINOGEN: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. GLOBAL CANCER VACCINES MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2017-2019
  • FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2019
  • FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2017-2019
  • FIGURE 06. MODERATE POWER OF SUPPLIERS
  • FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08. HIGH THREAT OF SUBSTITUTION
  • FIGURE 09. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10. HIGH COMPETITIVE RIVALRY
  • FIGURE 11. MARKET SHARE ANALYSIS, 2019
  • FIGURE 12. IMPACT ANALYSIS
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DENDRITIC CELLS (DC) CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIGEN/ADJUVENT CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR AND DNA CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PROSTATE CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PADIATRICS CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF ADULTS CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 24. ADVAXIS NET SALES, 2017-2019 ($MILLION)
  • FIGURE 25. AMGEN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 26. AMGEN: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 27. DYNAVAX TECHNOLOGIES: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 28. GENEREX BIOTECHNOLOGY: NET SALES, 2018-2019 ($MILLION)
  • FIGURE 29. GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 30. GSK: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 31. GSK: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 32. MERCK & CO., INC.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 33. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 34. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2019 (%)